Trial Profile

Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (anti-IL-8) for NSCLC or HCC

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 813160 (Primary) ; HuMax IL8 (Primary) ; Nivolumab (Primary)
Indications Liver cancer; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

17 Jan 2025 Planned End Date changed from 1 Sep 2024 to 31 Dec 2025.
17 Jan 2025 Planned primary completion date changed from 1 Oct 2024 to 31 Dec 2025.
17 Jan 2025 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com